Ipsen Alternatives & Competitors
12 companies similar to Ipsen — Engineers and develops bacterial-based protein therapeutics for the treatment of...
Companies similar to Ipsen
Sangamo Therapeutics, Inc.
We're committed to translating our ground-breaking science into genomic medicines that tra...
Brisbane, United States
Odyssey Therapeutics
Building a machine learning-based platform to develop novel therapeutics focusing on cance...
BlossomHill Therapeutics, Inc.
Addressing urgent unmet medical needs through deeper science, true originality, and rich e...
San Diego, United States
Rival Readout
Competing with Ipsen? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Jazz Pharmaceuticals
Identifying, developing and commercializing meaningful products that address unmet medical...
Dublin, Ireland
Vertero Therapeutics, Inc.
Pioneering science beyond the brain to treat neurodegenerative diseases at their source
Woburn, United States
EUSA Pharma
Part of Recordati Rare Diseases, the business unit dedicated to rare diseases in the Recor...
Hemel Hempstead, United K...
ROME Therapeutics
Harnessing the power of the repeatome to develop a new class of therapies for cancer and a...
Boston, United States
Skye Bioscience Inc.
Unlocking new therapeutic pathways for metabolic health
San Diego, United States
Bloomsbury Genetic Therapies
Dedicated to delivering the promise of gene therapy
London, United Kingdom
bluebird bio
Pursuing curative gene therapies to give patients and their families more bluebird days.
Somerville, United States
About Ipsen
Ipsen, founded in 2010, is a global biopharmaceutical company headquartered in France. The company specializes in engineering and developing bacterial-based protein therapeutics aimed at treating neurological, inflammatory, and endocrine diseases. Focusing on three critical therapeutic areas—Oncology, Rare Disease, and...
Research and development, Pharmaceutical commercialization, Clinical trial execution, Therapeutic innovation
Patients with oncology needs, Individuals living with rare diseases, Patients with neurodegenerative conditions, Healthcare providers, Pharmaceutical and biotech partners
Bacterial-based Protein Therapeutics, Neurological Diseases, Inflammatory Diseases, Endocrine Diseases, Oncology, Rare Disease, Neuroscience, Prostate Cancer, Neuroendocrine Tumors, Renal Cell Carcinoma, Pancreatic Cancer, Peptide Research, Toxin Research, External Innovation, Specialty Care
B2B, B2C
Product Sales, Licensing
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Ipsen: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Ipsen on 11 Mar 2026. The 12 companies listed here were last checked between 11 Mar 2026 and 3 Jul 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
